These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 11355156)

  • 1. A modified protocol to improve the detection of enhancing brain and spinal cord lesions in multiple sclerosis.
    Silver NC; Good CD; Sormani MP; MacManus DG; Thompson AJ; Filippi M; Miller DH
    J Neurol; 2001 Mar; 248(3):215-24. PubMed ID: 11355156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitivity of contrast enhanced MRI in multiple sclerosis. Effects of gadolinium dose, magnetization transfer contrast and delayed imaging.
    Silver NC; Good CD; Barker GJ; MacManus DG; Thompson AJ; Moseley IF; McDonald WI; Miller DH
    Brain; 1997 Jul; 120 ( Pt 7)():1149-61. PubMed ID: 9236628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantification of subtle blood-brain barrier disruption in non-enhancing lesions in multiple sclerosis: a study of disease and lesion subtypes.
    Soon D; Tozer D; Altmann D; Tofts P; Miller D
    Mult Scler; 2007 Aug; 13(7):884-94. PubMed ID: 17468443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A study of subtle blood brain barrier disruption in a placebo-controlled trial of natalizumab in relapsing remitting multiple sclerosis.
    Soon D; Altmann DR; Fernando KT; Giovannoni G; Barkhof F; Polman CH; O'Connor P; Gray B; Panzara M; Miller DH
    J Neurol; 2007 Mar; 254(3):306-14. PubMed ID: 17277910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials.
    Filippi M; Rovaris M; Capra R; Gasperini C; Yousry TA; Sormani MP; Prandini F; Horsfield MA; Martinelli V; Bastianello S; Kühne I; Pozzilli C; Comi G
    Brain; 1998 Oct; 121 ( Pt 10)():2011-20. PubMed ID: 9798753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple dose of gadolinium-DTPA increases the sensitivity of spinal cord MRI in detecting enhancing lesions in multiple sclerosis.
    Yousry TA; Fesl G; Walther E; Voltz R; Filippi M
    J Neurol Sci; 1998 Jun; 158(2):221-5. PubMed ID: 9702695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood-brain barrier permeability of normal appearing white matter in relapsing-remitting multiple sclerosis.
    Lund H; Krakauer M; Skimminge A; Sellebjerg F; Garde E; Siebner HR; Paulson OB; Hesse D; Hanson LG
    PLoS One; 2013; 8(2):e56375. PubMed ID: 23441184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pluriformity of inflammation in multiple sclerosis shown by ultra-small iron oxide particle enhancement.
    Vellinga MM; Oude Engberink RD; Seewann A; Pouwels PJ; Wattjes MP; van der Pol SM; Pering C; Polman CH; de Vries HE; Geurts JJ; Barkhof F
    Brain; 2008 Mar; 131(Pt 3):800-7. PubMed ID: 18245785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS.
    Filippi M; Yousry T; Campi A; Kandziora C; Colombo B; Voltz R; Martinelli V; Spuler S; Bressi S; Scotti G; Comi G
    Neurology; 1996 Feb; 46(2):379-84. PubMed ID: 8614498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis.
    Thorpe JW; Kidd D; Moseley IF; Kenndall BE; Thompson AJ; MacManus DG; McDonald WI; Miller DH
    Neurology; 1996 Feb; 46(2):373-8. PubMed ID: 8614497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term evolution of new multiple sclerosis lesions enhancing on standard and triple dose gadolinium-enhanced brain MRI scans.
    Rovaris M; Mastronardo G; Prandini F; Bastianello S; Comi G; Filippi M
    J Neurol Sci; 1999 Apr; 164(2):148-52. PubMed ID: 10402026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MRI evolution of new MS lesions enhancing after different doses of gadolinium.
    Rovaris M; Mastronardo G; Gasperini C; Prandini F; Yousry TA; Filippi M
    Acta Neurol Scand; 1998 Aug; 98(2):90-3. PubMed ID: 9724005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of magnetic resonance techniques in understanding and managing multiple sclerosis.
    Miller DH; Grossman RI; Reingold SC; McFarland HF
    Brain; 1998 Jan; 121 ( Pt 1)():3-24. PubMed ID: 9549485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving acute demyelinating lesion detection: which T1-weighted magnetic resonance acquisition is more sensitive to gadolinium enhancement?
    Amaral LLFD; Fragoso DC; Rocha AJD
    Arq Neuropsiquiatr; 2019 Jul; 77(7):485-492. PubMed ID: 31365640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serial gadolinium-DTPA of spinal cord MRI in multiple sclerosis: triple vs. single dose.
    Yousry I; Filippi M; Walther E; Gasperini C; Capra R; Yousry TA
    Magn Reson Imaging; 2000 Nov; 18(9):1183-6. PubMed ID: 11118774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative T1 mapping detects blood-brain barrier breakdown in apparently non-enhancing multiple sclerosis lesions.
    Donatelli G; Cecchi P; Migaleddu G; Cencini M; Frumento P; D'Amelio C; Peretti L; Buonincontri G; Pasquali L; Tosetti M; Cosottini M; Costagli M
    Neuroimage Clin; 2023; 40():103509. PubMed ID: 37717382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A preliminary study comparing the sensitivity of serial monthly enhanced MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in primary progressive multiple sclerosis.
    Filippi M; Rovaris M; Gasperini C; Capra R; Bastianello S; Kuhne I; Yousry TA
    J Neuroimaging; 1998 Apr; 8(2):88-93. PubMed ID: 9557146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diffusely abnormal white matter converts to T2 lesion volume in the absence of MRI-detectable acute inflammation.
    Dadar M; Mahmoud S; Narayanan S; Collins DL; Arnold DL; Maranzano J
    Brain; 2022 Jun; 145(6):2008-2017. PubMed ID: 34927199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of chemical fat-saturation pulse added to T1-weighted spin-echo sequence in evaluating gadolinium-enhancing brain lesions in multiple sclerosis.
    Sardanelli F; Schiavoni S; Iozzelli A; Fausto A; Aliprandi A; Mancardi GL; Filippi M
    Radiol Med; 2007 Dec; 112(8):1244-51. PubMed ID: 18080095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the sensitivity of MRI after double- and triple-dose Gd-DTPA for detecting enhancing lesions in multiple sclerosis.
    Gasperini C; Paolillo A; Rovaris M; Yousry TA; Capra R; Bastianello S; Filippi M
    Magn Reson Imaging; 2000 Jul; 18(6):761-3. PubMed ID: 10930786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.